The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
分析師的觀點:愛美醫療在8位專家眼中
In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics (NASDAQ:FOLD), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中,已有8位分析師爲Amicus Therapeutics(納斯達克:FOLD)發佈了評級,展示了從看好到看淡的各種觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級,展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $21.00, and a low estimate of $15.00. Observing a 3.8% increase, the current average has risen from the previous average price target of $16.86.
分析師通過其對12個月價格目標的評估提供更深入的見解,顯示平均目標爲17.5美元,最高估值爲21.00美元,最低估值爲15.00美元。觀察到3.8%的增長,當前平均數已從之前的16.86美元上升。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析:詳細分析
The perception of Amicus...
愛美醫療...
登入免費觀看全文
登入/註冊